Benzinga | Jan 27, 2021 08:03AM EST

Scholar Rock Highlights Presentation Of Pre-Clinical Data For SRK-181 At TGF for Immuno-Oncology Drug Development Summit On Jan. 28, 2021 At 12:30 p.m. EST

Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGF? for Immuno-Oncology Drug Development Summit.

"Inhibition of TGF?1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy" will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an overview of the preclinical data demonstrating selective inhibition of TGF?1 activation with SRK-181-mIgG1 (murine version of SRK-181) induces combination treatment effects with anti-PD-1 on tumor growth in checkpoint inhibition therapy-resistant tumors as well as an improved preclinical toxicity profile compared to less selective TGF? inhibition.

Scholar Rock will also be participating in a panel discussion titled "Debating the Best Approach to Target TGF-?" on January 27th, 2021 at 10:45 am EST.